A few instances of the therapeutic use of the BRAF inhibitor vemurafenib in MM have been reported [7, 9], and it is to be hoped that more precise indications concerning its efficacy will emerge from the ongoing phase II Basket study (NCT01524978) of vemurafenib in patients with BRAF V600E mutation-positive cancers, which also includes MM patients [33]. This evidence concerns the gene BRAF and Miyoshi myopathy.